Wyeth and MedImmune have ended their partnership for the influenza vaccine FluMist after the spray application failed to meet expectations during its first year. Wyeth said it plans to concentrate on its own vaccine business without MedImmune, which said in March it would continue with the drug, but has scheduled a news conference this week to announce its intentions after the Wyeth pullout.

Full Story:

Related Summaries